Literature DB >> 12399202

CD4+ and CD8+ mediated cellular immune response to recombinant influenza nucleoprotein.

C Gschoesser1, G Almanzar, U Hainz, J Ortin, D Schonitzer, H Schild, M Saurwein-Teissl, B Grubeck-Loebenstein.   

Abstract

The stimulatory properties of soluble recombinant influenza nucleoprotein (NP) on purified CD4(+) and CD8(+) T cells from young and elderly individuals were studied. Recombinant influenza NP failed to induce proliferation of resting CD4(+) and CD8(+) T cells in the absence of IL-2. Addition of small amounts of IL-2, however, led to strong proliferation of resting CD4(+) and CD8(+) T cells from young and elderly donors. NP-reactive CD4(+) and CD8(+) T cell lines from both age groups grew equally well under long-term culture conditions. T cell lines raised to live influenza virus could recognize recombinant influenza NP and showed a substantial proliferative response. Stimulation of CD8(+) T cells is presumably due to cross-presentation, as EBV-transformed MHC class I-positive cell lines, which are incapable of antigen processing, stimulated live influenza virus-reactive CD8(+) T cell lines when loaded with NP-derived immunodominant peptides but not following loading with the whole NP molecule. Vaccines containing recombinant influenza NP might confer cross-protective immunity and could therefore be especially useful in cases of major epidemics or pandemics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399202     DOI: 10.1016/s0264-410x(02)00355-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Immunodominant peptides from conserved influenza proteins--a tool for more efficient vaccination in the elderly?

Authors:  Giovanni Almanzar; Dietmar Herndler-Brandstetter; Sandra Vega Chaparro; Brigitte Jenewein; Michael Keller; Beatrix Grubeck-Loebenstein
Journal:  Wien Med Wochenschr       Date:  2007

Review 2.  Development of universal influenza vaccines based on influenza virus M and NP genes.

Authors:  M Zheng; J Luo; Z Chen
Journal:  Infection       Date:  2013-11-01       Impact factor: 3.553

3.  Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus.

Authors:  Dongming Zhou; Te-Lang Wu; Kristel L Emmer; Raj Kurupati; Steven Tuyishime; Yan Li; Wynetta Giles-Davis; Xiangyang Zhou; Zhiquan Xiang; Qin Liu; Sarah J Ratcliffe; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

4.  Structure of the influenza virus A H5N1 nucleoprotein: implications for RNA binding, oligomerization, and vaccine design.

Authors:  Andy Ka-Leung Ng; Hongmin Zhang; Kemin Tan; Zongli Li; Jin-huan Liu; Paul Kay-Sheung Chan; Sui-Mui Li; Wood-Yee Chan; Shannon Wing-Ngor Au; Andrzej Joachimiak; Thomas Walz; Jia-Huai Wang; Pang-Chui Shaw
Journal:  FASEB J       Date:  2008-07-09       Impact factor: 5.191

Review 5.  Universal influenza vaccines: from viruses to nanoparticles.

Authors:  Ye Wang; Lei Deng; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Expert Rev Vaccines       Date:  2018-11-02       Impact factor: 5.217

6.  Immunosenescence-Related Transcriptomic and Immunologic Changes in Older Individuals Following Influenza Vaccination.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Ann L Oberg; Michael T Zimmermann; Diane E Grill; Gregory A Poland
Journal:  Front Immunol       Date:  2016-11-02       Impact factor: 7.561

7.  Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1.

Authors:  Oleg P Zhirnov; Elena I Isaeva; Tatyana E Konakova; Galini Thoidis; Lyudmila M Piskareva; Irina I Akopova; Alex Kartashov; Anatoly D Altstein; Petr O Ilyinskii; Alexander M Shneider
Journal:  Influenza Other Respir Viruses       Date:  2007-03       Impact factor: 4.380

Review 8.  The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses-Not Just Another Brick in the Viral Nucleocapsid.

Authors:  Maja Šantak; Zrinka Matić
Journal:  Viruses       Date:  2022-03-03       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.